Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2021 | TARGIT-IORT for early breast cancer

Prof. Jayant Vaidya, MBBS, PhD, FRCS, FRCS(Gen), University College London, London, UK, discusses long-term follow-up data and outcomes from the Phase III TARGIT-A trial (NCT00983684) comparing targeted intraoperative radiotherapy (IORT) [targit.org.uk] to external beam radiation therapy (EBRT) in patients with early breast cancer. Single dose TARGIT-IORT during lumpectomy was as effective as EBRT and resulted in lower mortality rates from other causes. Prof. Vaidya additionally highlights the environmental benefit of TARGIT-IORT as a result of less travel required by patients, as well as the potential abscopal effect from TARGIT-IORT. This interview took place at the National Cancer Research Institute (NCRI) Festival 2021.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.